BMRA - Biomerica reports Q2 results business updates

Biomerica (BMRA): FQ2 Net Loss of $1.49M.Revenue of $1.37M (-14.4% Y/Y).Business Updates:Biomerica expects completion of enrollment of its Irritable Bowel Syndrome Diagnostic-Guided Therapy clinical trial by end of April, 2021The company says FDA is actively reviewing its EUA submission for its first of its kind “at-home” blood collection kit used with the Biomerica COVID-19 IgG ELISA lab test system.Further, Biomerica has received first large orders for its CE-marked, simple to use 15-minute COVID-19 antigen rapid testPress Release

For further details see:

Biomerica reports Q2 results, business updates